Key facts
- Notable investors include Creative Destruction Lab, WTIA Startup Program, Blackwood Healthcare Breakthroughs, Debiopharm Innovation Fund, Desai Accelerator — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for ModernVivo
- ·The full record, as it builds
Funding rounds
No funding rounds for ModernVivo are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ModernVivo
Developer of an AI-powered literature review platform designed to review for superior in vivo study design. The company's platform utilizes machine learning and natural language processing technologies to design optimized preclinical in vivo models, improving drug translation and clinical success while reducing development costs, enabling users to obtain well-performing in vivo models, which are pivotal for successful drug development.
- Sector
- Information Technology
- HQ
- Seattle, WA, United States
- Founded
- 2022
- Employees
- 8
- Website
- modernvivo.com/
- Ownership
- Privately Held (backing)
ModernVivo doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ModernVivo shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ModernVivo in its N-PORT filings yet. We sweep new filings monthly.